Quantum Computing, INmune Bio Partner on Alzheimer's Treatment Research

BOCA RATON, Fla. and HOBOKEN, N.J., Oct. 14, 2026 /CourierPR/ -- INmune Bio Inc. and Quantum Computing Inc. have announced a collaboration aimed at leveraging quantum computing, artificial intelligence (AI), and data analytics to identify new potential applications for XPro, INmune Bio's investigational treatment for Alzheimer's disease and other diseases. The partnership combines INmune Bio's extensive clinical research, spanning from pre-clinical studies through four clinical trials, with Quantum Computing Inc.'s Dirac-3S quantum optimization machine.

The collaboration will utilize the Dirac-3S alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success. This engagement marks Quantum Computing Inc.'s first commercial customer in the pharmaceutical and biotechnology market, expanding the application of quantum computing to drug development.

INmune Bio, a publicly traded late-stage biotechnology company, is focused on developing treatments that target the innate immune system to fight disease. The Company's clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes. INmune Bio is currently advancing two late-stage product platforms toward registrational milestones: CORDStrom™, a human umbilical cord-derived mesenchymal stromal cell platform, and XPro1595™, a Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function.

Quantum Computing Inc., an integrated quantum photonics company, is developing and manufacturing technologies that use light to compute complex information, capture hard-to-detect signals, and communicate more securely. The Dirac-3S entropy quantum optimization machine, alongside AI and conventional analytics, will be used to look for patterns and relationships across datasets that could help researchers better understand treatment responses, identify promising patient populations, and prioritize new indications for further study.

The collaboration offers INmune Bio a new way to evaluate the broader potential of XPro and prioritize future development opportunities. For Quantum Computing Inc., it represents an opportunity to showcase how its room-temperature, low-power quantum computing technology can be applied to complex, real-world problems in pharmaceutical research.

The work is also intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications. The Stage 1 engagement will compare results from Quantum Computing Inc.'s quantum optimization machine with appropriate conventional statistical and machine-learning methods, evaluating which approaches are best suited to different parts of the analysis.

INmune Bio's XPro1595™ is designed to selectively inhibit soluble tumor necrosis factor (TNF), a protein involved in inflammation, while preserving other TNF functions important to the immune system. The Company is investigating its potential in neurological and rare diseases where this targeted approach may offer a therapeutic benefit.

Quantum Computing Inc. is headquartered in Hoboken, New Jersey, and its technologies are designed to operate at room temperature and low power, without the specialized cooling infrastructure required by many quantum approaches. These advantages enable deployment across computing and AI, secure communications, sensing and imaging, aerospace and defense, and other demanding applications.

INmune Bio's CORDStrom™ is a proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. The platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.

The companies plan to test where quantum optimization adds value to their analysis, with the goal of establishing a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications. This collaboration represents a significant step in the application of quantum computing to drug development, offering INmune Bio a new tool to explore the potential of XPro and Quantum Computing Inc. a platform to showcase its technology in a real-world setting.

The Litigation Reform Act of 1995, as amended, and the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, all contain provisions that regulate the use of forward-looking statements. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin)